Led · Seed · Jul 2026

Chiron operates a multi-condition AI platform designed to extend care beyond episodic clinic visits by creating continuous feedback loops between patients and providers. The company is expanding its platform into cardiometabolic health, gastrointestinal disorders, and women’s health. Chiron emphasizes an intelligent, integrated self-management layer that complements clinician care. The team is led by co-founder and CEO Carron Manning. Financially, the company recently raised a £900K seed round led by THENA Capital with participation from Arāya Ventures. The article does not disclose revenue, users, or prior funding rounds.

Led · Seed · May 2026

Zonova develops Z-ROS®, an antimicrobial additive designed to be engineered directly into the polymers of medical devices to create infection-resistant surfaces. The company's licensing model allows global device manufacturers to integrate Z-ROS® into existing product lines without rebuilding supply chains. Early laboratory studies reported by Zonova show greater than 99.99% effectiveness against MRSA and other organisms commonly involved in hospital-acquired infections. Following the recent seed raise, Zonova plans to prioritise integration into vascular access devices, with urology, women's health and orthopaedics planned next. The company has added Dr Pamela Walker Geddes to its board as part of the recent financing. Financially, Zonova has just closed a £2.1m seed round led by THENA Capital with participation from multiple impact and angel investors.

Led · Seed · Sep 2025

Salient Bio develops microbiome-based, non-invasive diagnostics using its proprietary SIGNAL platform, which applies automation, microbiome data analysis, and machine learning to generate disease signatures. The company is commercializing an at-home IBD diagnostic test intended to accelerate diagnosis and distinguish IBD from conditions with similar symptoms, potentially reducing unnecessary colonoscopies. It plans to leverage SIGNAL to accelerate research into conditions that disproportionately affect women and expand its women’s health offerings. Salient Bio operates an ISO 17025 accredited testing and prototyping laboratory in London focused on microbiome analysis, process standardization, automation, and machine learning-based data analysis. The company has raised a £2.35 million seed round to support the commercial launch of its IBD test. Founders Marta Ciechonska and Miles Priestman emphasize accessible, non-invasive testing solutions to shorten diagnostic timelines and enable earlier treatment.

Participated · Equity · Jul 2025

Plexāā is a UK-based MedTech company whose flagship product, BLOOM43, is a fully wearable medical device and companion app designed to supraphysiologically precondition skin ahead of breast cancer surgery and reconstruction. BLOOM43 uses intermittent thermal preconditioning to trigger heat-shock proteins, causing vasodilation and increased blood flow; proof-of-concept clinical trials have shown reductions in wound-healing complications. The device and app have demonstrated improvements in patient experience and surgical readiness, and the company has secured multiple partners for an imminent U.S. commercial launch. Plexāā plans to expand the BLOOM43 platform into additional surgical specialties, including obstetrics (C-sections), orthopaedics, and general and vascular surgery. Financially, Plexāā recently closed a $4.5 million funding extension and has received over $1.6 million in NIHR i4i grant funding plus $1.3 million from Thena Capital, strengthening its position ahead of a planned Series A.